Effectiveness of bipolar disorder treatment may depend on patient’s genes

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

A group of international scientists investigated how a patient’s genetic make-up could impact the effects of the drug lithium, which is used to treat mood disorders including bipolar and depression.

Despite being the most effective bipolar treatment available, the study found that lithium only works for about a third of the people who take it.

University of New South Wales’ head of psychiatry Philip Mitchell, one of the co-authors of the study, said they had found that while one third of patients did partially well, one third did not respond at all.

“Bipolar disorder is a very difficult condition to treat,” he said.

“It’s very disruptive and also over time, it’s recurrent, so people have repeated episodes of manic highs and depressed lows which really damage people’s lives.

“The imperative is to stop those episodes recurring. When you get the treatment correct though, it can just make an enormous difference to people’s lives.”

The study, published in the Lancet journal, was a collaboration between researchers all over the world from the International Consortium on Lithium Genetics.

The researchers concluded that different genetic markers may determine how well patients respond to the lithium.

“There’s been growing evidence that the response to lithium appears to run in families, which has suggested that there are probably genetic determinants of who benefits from lithium,” Professor Mitchell said.

Read full, original post: Bipolar treatment: Genetics change people’s response to lithium, study finds

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-11-17-at-12.18.09-PM
Challenging glyphosate fear-mongering: Statewide Nebraska study finds no link between weedkiller use and non-Hodgkin lymphoma
Screenshot-2026-11-16-at-2.37.32-PM
30 years of GMO farming: Is the boom in glyphosate and glufosinate use harming the environment? Data show they’re the most sustainable choice
Soybean Harvest in Cupped Hands
30 years of GMO farming: Defying cynics, we’ve had larger harvests, lower costs, and $385 billion in added global farmer income
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Stormlit Portrait Over Golden Mountains
Searching for life where no one thought to look: A renowned astrophysicist’s seemingly quixotic quest to explore Venus’s clouds
Screenshot-2026-11-19-at-7.54.57-PM
European General Court sides with scientists, dismisses activist claims that glyphosate is toxically dangerous
Screenshot-2026-11-13-at-10.02.02-AM
Viewpoint: Why it’s such a big deal that under Trump-RFK Jr., the U.S. has lost its ‘measles-free’ status  
Nurturing Care Beneath the Crunchy Moms Logo
Crunchy Moms disinformation flood: Zuckerberg's Facebook has opened floodgates on measles and vaccines
Screenshot-2026-11-19-at-7.23.23-PM
Viewpoint: After a yearlong hiatus, the U.S. Preventive Services Task Force is back in business—gutted by RFK Jr. and promoting junk science
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.